Search the Newsreel

Talphera signals ~$200,000 annual U.S. CRRT procedures in 2027 market sizing as NEPHRO CRRT reaches 75% enrollment

Earnings Call Insights: Talphera (TLPH) Q2 2026 MANAGEMENT VIEW * “With all of our final clinical sites now activated, we have reached 75% enrollment in the NEPHRO CRRT study,” said CEO Vincent Angotti, adding, “We remain on track to complete enrollment in the NEPHRO …

TLPH Stock Price and Chart — NASDAQ:TLPH

This article provides a detailed overview of Talphera, Inc. (TLPH) stock, including its current price, historical performance, key financial statistics, and analyst ratings. It also features information on recent earnings reports, future earnings expectations, company details, and answers frequently asked questions about the stock. …

Talphera Inc (TLPH) (Q2 2026) Earnings Call Highlights: NEPHRO Study Enrollment Hits 75% as KDIGO Endorsement Expands Market Opportunity

Talphera Inc. (TLPH) announced significant progress in its Q2 2026 earnings call, with 75% enrollment in its NEPHRO CRRT study and the 2026 KDIGO guidelines now referencing nafamostat as an acceptable regional anticoagulant. The company also reported a cash balance of $17.1 million and …

Earnings call transcript: Talphera Q2 2026 meets estimates as stock slips

Talphera Inc. reported a Q2 2026 loss of negative $0.06 per share, matching Wall Street estimates, but its stock declined. The company is advancing its nafamostat program for continuous renal replacement therapy (CRRT), with its NEPHRO-CRRT trial 75% enrolled and a potential market for …

Talphera (NASDAQ:TLPH) Issues Earnings Results, Meets Estimates

Talphera (TLPH): Rosalind entities report 9.9% beneficial ownership cap

Rosalind Master Fund L.P. and related entities have reported a 9.9% beneficial ownership in Talphera, Inc. (TLPH) through a Schedule 13G/A filing. The filing indicates beneficial ownership of 5,169,501 common shares, representing approximately 9.96% of Talphera's outstanding stock. This percentage is capped due to …

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Talphera, Inc. announced its second-quarter 2026 financial results and provided a corporate update, highlighting that its NEPHRO CRRT clinical study of nafamostat is 75% enrolled and expected to be completed this year. The company noted that draft 2026 KDIGO guidelines now include nafamostat as …

Talphera Inc expected to post a loss of 7 cents a share - Earnings Preview

Talphera Inc is projected to report a loss of 7 cents per share in its upcoming earnings announcement. This information is presented as an earnings preview. The full article is available through a subscription service on TradingView.

Talphera (NASDAQ:TLPH) Upgraded at Wall Street Zen

Talphera (NASDAQ:TLPH) was upgraded to a "Hold" rating by Wall Street Zen, aligning with the overall "Hold" consensus among analysts, who have an average price target of $3.00. The company reported a narrower-than-expected quarterly loss of $0.04 per share, beating estimates. Institutional ownership is …

Talphera Inc (TLPH) Stock News Today

This article from TradingKey provides current stock information for Talphera Inc (TLPH), including its market cap and recent trading activity. It states that more news, earnings, and analyst ratings will be updated soon, indicating it is a placeholder for future developments. The article encourages …

Talphera Inc (TLPH) Earnings Forecast: Future EPS & Revenue Growth Estimates

Talphera Inc (TLPH) has an earnings forecast score of 8.00, placing it 58th in the Pharmaceuticals industry. Analysts have set an average price target of $3.50, with a range from $3.00 to $6.00, and a "Buy" rating based on three analysts' opinions. The company's …

Enterprise value to EBIT forward of Talphera, Inc. – DUS:R5XA

This page from TradingView provides financial data for Talphera, Inc. (R5XA) on the Dusseldorf Stock Exchange, specifically focusing on its enterprise value to EBIT forward metric. The content emphasizes the financial overview of the company, indicating that no trades were made and the market …

Talphera will webcast its second-quarter financial update Aug. 12

Talphera (Nasdaq: TLPH) announced it will host a conference call and webcast on Wednesday, August 12, 2026, at 4:30 p.m. ET to discuss its second-quarter 2026 financial results and recent business progress. Investors can access the call via dial-in numbers provided or a live …

Talphera schedules Q2 2026 results conference call and webcast

Talphera has scheduled a conference call and webcast for August 12, 2026, to discuss its second-quarter 2026 financial results and recent business developments. A replay of the webcast will be available for 90 days on the company's website. This news brief was generated by …

Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026

Talphera, Inc. announced it will report its second-quarter 2026 financial results on Wednesday, August 12, 2026. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the results and recent business progress. Talphera is a specialty pharmaceutical company developing …

Talphera Inc (TLPH) Risk Assessment: Volatility, Financial Risk & Investment Risk

Talphera Inc (TLPH) has a risk assessment score of 2.24, ranking 128 out of 156 in the Pharmaceuticals industry. The stock's beta of 0.77 suggests it tends to underperform in bull markets but decline less in bear markets. The article details various risk metrics …

Talphera Inc (TLPH) Financial Health: Profitability & Balance Sheet Analysis

Talphera Inc (TLPH) has a weak financial status and low operating efficiency, ranking 154 out of 155 in the Pharmaceuticals industry with a financial score of 5.43. The company reported a 100% year-over-year decrease in quarterly revenue and a 1.43% decrease in net profit. …

Talphera, Inc. Revenue Breakdown – MUN:R5XA

Talphera, Inc. (MUN:R5XA) generated a total revenue of 23.84K EUR last year, a significant decrease from 589.81K EUR in the previous year. The "Innovative Therapies" segment was the primary revenue driver, accounting for all 23.84K EUR. The United States was the sole geographical contributor …

Talphera Inc (TLPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Talphera Inc (TLPH), detailing its current price momentum, support and resistance levels, and signals from various technical indicators and moving averages. The stock currently ranks 17th in the Pharmaceuticals industry for price momentum, and its price is …

Talphera Inc (TLPH) Institutional Confidence

Talphera Inc (TLPH) has an institutional shareholding score of 3.00, placing it 92nd out of 155 in the Pharmaceuticals industry. The institutional shareholding proportion is 40.00%, showing a 0.70% quarter-over-quarter increase. James Simons is the largest institutional shareholder, holding 0.48% of outstanding shares.

Talphera Inc (TLPH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Talphera Inc (TLPH) based on business segments for FY2022, as of an update on March 5, 2025. It details revenue contributions from DSUVIA and DZUVEO, noting that other segments like Zalviso and royalty revenue had no contribution. …

Talphera Inc (TLPH) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Talphera Inc (TLPH), listing its major shareholders and their respective proportions, including CorMedix Inc, Rock Springs Capital Management LP, and Rosalind Advisors, Inc. It also provides a breakdown of shareholder types such as corporations and hedge funds, …

Talphera Inc (TLPH) Cash Flow

This article provides a deep dive into Talphera Inc's (TLPH) cash flow statements, offering both annual and quarterly data to assess its financial health. It details operating, investing, and financing cash flows, along with changes in working capital and free cash flow. The content …

Talphera Inc (TLPH) Income Statement

This article provides the quarterly and annual income statements for Talphera Inc (TLPH), detailed financial data including revenue, operating expenses, and net income, and a set of frequently asked questions to help users understand how to interpret the financial statements. It shows that Talphera …

TLPH|Talphera Inc|Price:1.350|Chg%:-0.020

Talphera Inc. (TLPH) is a specialty pharmaceutical company with relatively stable fundamentals and significant growth potential, though its valuation is considered fairly valued within the Pharmaceuticals industry. Institutional ownership is high, and analysts have given it "Buy" ratings with a target price suggesting substantial …